Imodium Instant Smelttablet (Loperamide Hydrochloride)

Loperamide acts as an agonist at µ‑opioid receptors in the intestinal wall. This reduces the release of acetylcholine, slows smooth‑muscle contractions, prolongs transit time, and enhances water and electrolyte absorption, resulting in firmer stools and fewer bowel movements.

The appropriate dose of Imodium Instant Smelttablet is determined by a qualified healthcare professional based on the patient’s condition, age, and response. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety data for loperamide in pregnancy and lactation are limited. Healthcare providers usually weigh the potential benefits against possible risks before prescribing. Women who are pregnant or breastfeeding should discuss use with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Loperamide is a peripheral µ‑opioid receptor agonist that does not cross the blood‑brain barrier significantly, offering antidiarrheal efficacy with minimal central opioid effects. Compared with diphenoxylate‑atropine, loperamide has a lower risk of central sedation and does not contain an anticholinergic component.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain tablet integrity.

The tablet is an oral disintegrating formulation that dissolves rapidly on the tongue without water. Patients should place the tablet on the tongue and allow it to dissolve completely before swallowing any residual saliva.

Serious risks include severe constipation that can lead to bowel obstruction, toxic megacolon, and rare cardiac events such as QT‑interval prolongation. Patients should seek immediate medical attention if they experience abdominal pain, vomiting, or signs of cardiac irregularities.

Individuals with known hypersensitivity to loperamide, active bacterial enterocolitis, pseudomembranous colitis, or those taking certain CYP3A4 inhibitors should avoid the product. It is also contraindicated in patients with severe hepatic impairment unless specifically directed by a physician.